PsyBio Therapeutics Corp. announced that it has expanded its ongoing relationship with Miami University in Oxford, Ohio ("Miami University") by leasing dedicated research and development ("R&D") laboratory space. The laboratory space at Miami University is expected to provide a comprehensive, research environment in which PsyBio's ever-expanding portfolio of compounds can be more readily and rapidly developed.

This continued collaboration with Miami University is anticipated to expedite progress toward PsyBio filing an Investigational New Drug application with the United States Food and Drug Administration.